Hey readers! 👋 Big news dropped this week from Dexcom's Investor Day, and if you've been wondering what's next after the G7, wonder no more. The G8 is officially on the horizon, and it's bringing a seriously smaller sensor, smarter algorithms, and some genuinely interesting adaptive tech. We're diving deep into what this means for all of us, plus catching up on closed-loop pregnancy data, early screening wins, mental health in pediatric care, and more. Let's get into it!
📡 The Main Event: Dexcom G8 Revealed
Dexcom Reveals Details of G8 Continuous Glucose Monitoring Device - Dexcom shared detailed specs on its next-generation CGM at its Investor Day, calling the G8 a "completely new product platform" rather than an incremental update. – MD+DI
Here's what we know: the G8 will be 50% smaller than the current G7, built on a redesigned silicon chip with updated algorithms and advanced sensing capabilities. The most interesting technical detail? The sensor will measure signals beyond just glucose, allowing it to adapt to your individual physiology in real time. The goal is to reduce those frustrating outlier readings that can throw off your day (or your closed-loop system).
"It's a precise sensor that's going to adapt to the body over time, and we expect this to really enhance the user experience."
Dexcom is retaining factory calibration, so no fingerstick calibrations needed, while adding this self-adapting layer on top. They're also maintaining the 15-day wear time as a baseline. On the business side, Dexcom expects manufacturing costs to be at least 10% lower than G7, which could eventually translate to savings for users.
Dexcom unveils next-gen G8 CGM system - Additional reporting confirms FDA submission is planned for next year, with a commercial launch targeted for late 2027 or early 2028. – Drug Delivery Business
A few things worth noting: Dexcom is also working on ketone and multi-analyte sensing capabilities that would come after the G8 launch. And they're pushing to expand Medicare coverage for type 2 non-insulin-using patients, which could double the covered U.S. addressable market. For the T1D community, the accuracy improvements matter most. If the adaptive algorithms deliver on reducing variability tied to individual physiology, that's meaningful for everyone relying on CGM data to dose insulin, whether manually or through an automated system.
Dexcom Unveils G8 with Advanced Sensing and AI Features - Alongside the G8 hardware, Dexcom introduced Stelo app updates including trend tracking, pattern analysis, AI-powered coaching, and a virtual assistant. – HLTH
The timeline feels realistic but not imminent. Late 2027 at the earliest means we're looking at roughly two years before this reaches anyone's arm. Regulatory processes can always shift things, so patience will be key.
🤰 Closed-Loop Insulin Delivery in Pregnancy
Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes - A multicenter UK trial found that hybrid closed-loop therapy (CamAPS FX) significantly improved time in range for pregnant women with T1D compared to standard insulin therapy. – NEJM
The numbers: 68.2% time in the pregnancy-specific target range (63-140 mg/dL) with closed-loop versus 55.6% with standard care, an adjusted difference of 10.5 percentage points. Benefits included less hyperglycemia, more overnight time in range, and lower HbA1c, with no unanticipated safety concerns. For anyone navigating T1D and pregnancy, this is solid evidence supporting automated insulin delivery during one of the most demanding periods of diabetes management.
🔬 Research & Immunotherapy Updates
Michigan teen gets type 1 diabetes therapy to delay need for insulin - A 14-year-old became the first patient at Corewell Health to receive TZield (teplizumab) after early screening caught Stage 2 T1D before symptoms appeared. – Detroit Free Press
This story highlights why early screening matters. Grayson's father has T1D, which qualified him for TrialNet screening. Autoantibodies were detected before any symptoms, and clinicians monitored his progression into Stage 2, when TZield could be administered. TZield has been shown to delay the median need for insulin by about 2.7 years. Screening also dramatically reduces hospitalization risk from diabetic ketoacidosis, down to roughly 3%.
"This is the first time we can actually delay the progression of type 1 diabetes and alter its course, which is a really big deal," said Dr. Nader Kasim.
Teplizumab and Beta-Cell Function in Newly Diagnosed T1D - The PROTECT trial showed teplizumab preserved beta-cell function at week 78 in children and adolescents, though key secondary clinical outcomes didn't reach significance. – NEJM
CU Anschutz Researchers Discover New Clues to Delaying T1D - Blocking the enzyme cathepsin D reduced hybrid insulin peptide formation and slowed disease progression in mouse models. – Debra Melani
GLP1-E2 plus low-dose anti-CD3 combination therapy - Combining immune modulation with beta-cell-targeted GLP-1 reduced diabetes incidence to 38% in NOD mice, with protection lasting weeks after treatment ended. – PubMed
🧠 Mental Health in Pediatric T1D
Beyond A1c: Mental Health Integration in Pediatric Type 1 Diabetes Care - A narrative review finds youth with T1D face elevated rates of depression, anxiety, diabetes distress, and disordered eating, and argues for embedding behavioral health professionals directly into diabetes care teams. – PubMed
This review makes a compelling case that numbers on a CGM screen are only part of the picture. Programs that co-locate mental health support within diabetes clinics show improved engagement and quality of life. The authors recommend standardized psychosocial screening, stepped-care models matched to symptom severity, and hybrid telehealth options. If you're a parent or caregiver feeling the weight of diabetes management, this validates what many of you already know: the emotional side deserves just as much clinical attention.
🎙️ Worth a Listen
Practical PACEs: Routines, Safe Spaces, and T1D Resilience - Scott and Erika explore how predictable routines, hobbies, and supportive environments build resilience beyond clinical management. – Juicebox Podcast
🔗 Quick Hits
TrialNet Pathway to Prevention Screening - Free screening available for relatives of people with T1D, capable of detecting early-stage disease years before symptoms. – TrialNet
Residual C-Peptide Secretion editorial - Many T1D patients retain some beta-cell function for years after onset, and preserving it is linked to meaningful clinical benefits. – NEJM
That's your week! The G8 timeline gives us something concrete to look forward to, and the research pipeline continues to move in encouraging directions. As always, talk to your care team before making any changes based on what you read here.
Have thoughts on the G8 or anything else? Hit reply, we'd love to hear from you. 💬
Made with ❤️ by Data Drift Press